

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Siemens Healthcare : CT (2010-2011-2012) - Servier : Imaging (2010-2011-2012) - Guerbet : Imaging (2010-2011-2012) - Siemens Healthcare : Imaging (2010-2011) - Bayer Healthcare : Imaging (2010-2011) <p>Additional Information declared:</p> <p>14/05/2013 Same relationships as last year, nothing new to declare.</p> <p>31/07/2013 NO new information</p>
Andreotti Felicita	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Anticoagulant agent (2010) - Bristol Myers Squibb : Anticoagulant agent (2010) - Astra Zeneca : Antiplatelet agent (2010) - Daiichi Sankyo : Antiplatelet agent (2010) - Eli Lilly : Antiplatelet agent (2010) - Bayer Healthcare : Antiplatelet agent; Anticoagulant agent (2010) - Pfizer (see also BMS) : apixaban (2012) - BMS-Pfizer : apixaban, cardiovascular metabolism (2012) - Bayer Schering Pharma : aspirin, rivaroxaban (2012) - Amgen : dyslipidemia (2012) - Daiichi Sankyo : edoxaban (2012) - Eli Lilly : prasugrel (2012)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Andreotti Felicita	<p>Additional Information declared:</p> <p>09/08/2013 Same relationships as of March 2013, i.e. no changes to declare.</p>
Arden Chris	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulation (2011-2012) - Boehringer-Ingelheim : Atrial Fibrillation. (2010) - Sanofi Aventis : Atrial Fibrillation. (2010) - Pfizer : Heart Failure. (2010) - Servier : Heart Failure/angina. (2010) - Servier : Research and travel grants (2011-2012) - St Jude Medical : Stroke prevention in AF (2011-2012) - Pfizer : heart failure (2011-2012) - Sanofi Aventis : Atrial Fibrillation. (2010) <p>Additional Information declared:</p> <p>19/05/2013 No declarations to add.</p> <p>06/08/2013 No declarations to add.</p> <p>06/08/2013 Speaker fee - Menarini</p>
Budaj Andrzej	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban (2010-2011-2012) - Novartis : canakinumab (2012)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Budaj Andrzej	<ul style="list-style-type: none"> - Boehringer-Ingelheim : dabigatran (2010-2011-2012) - GlaxoSmithKline : darapladib (2012) - GlaxoSmithKline : darapladib (2010-2011) - Sanofi Aventis : dronedarone (2010-2011) - Novartis : elinogrel (2010) - Sanofi Aventis : glargine (2011-2012) - Eli Lilly : prasugrel (2010) - Duke Institute : prasugrel (2011-2012) - Astra Zeneca : ticagrelor (2012) - Astra Zeneca : ticagrelor (2010-2011) - Merck Sharp & Dohme : vorapaxar (2010) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban (2010-2011-2012) - Novartis : canakinumab (2012) - Boehringer-Ingelheim : dabigatran (2010-2011-2012) - GlaxoSmithKline : darapladib (2010-2011-2012) - Sanofi Aventis : dronedarone (2010-2011) - Astra Zeneca : ticagrelor (2010-2011-2012) <p>Additional Information declared:</p> <p>11/06/2013 Additionally to 2012 declaration: personal and institution Duke Clinical Research Institute /Sanofi Aventis product: ALIROCUMAB Investigator fee</p>

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Bugiardini Raffaele	<p>None</p> <p>Additional Information declared:</p> <p>30/07/2013 'same relationships as 2012 i.e. no changes to declare':</p>
Crea Filippo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Atorvastatin (2010-2011-2012) - Boehringer-Ingelheim : Dabigatran (2010-2011-2012) - GlaxoSmithKline : Darapladip (2010-2011-2012) - Sanofi Aventis : Prasugrel (2010-2011-2012) - Astra Zeneca : Rosuvastatin (2010-2011-2012) - Chiesi Pharma : Rosuvastatin (2010-2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Pfizer : Atorvastatin (2010-2011-2012) - Sanofi Aventis : Prasugrel (2010-2011-2012) - Chiesi Pharma : Rosuvastatin (2010-2011-2012) <p>No additional information for the 2013 January - August period was submitted</p>
Cuisset Thomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medicines Company : Anticoagulant agent (2012) - Eli Lilly : Antiplatelet (2012) - Astra Zeneca : Antiplatelet Drug (2012) - Daiichi Sankyo : Antiplatelet drug (2012) - Iroko Cardio : Antiplatelet drug (2012)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Cuisset Thomas	<ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet Therapy (2010-2011) - Daiichi Sankyo : Antiplatelet Therapy (2010-2011) - Eli Lilly : Antiplatelet Therapy (2010-2011) - Abbott : Device (2010-2011) - Biosensors : Device (2012) - Boston Scientific : Device (2010-2011-2012) - Edwards Lifesciences : Device (2010-2011) - Terumo Inc : Device (2012) - Abbott Vascular : Device (2012) - Cordis : Device (2010-2011) - Eli Lilly : Medications (2012) <p>No additional information for the 2013 January - August period was submitted</p>
Di Mario Carlo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : Biomatrix stent (2010-2012) - Abbott Vascular : Xience stent (2010-2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Icaria : Cardiac remodelling (2010-2012) - Daiichi Sankyo, Eli-Lilly : Prasugrel (2010-2012) - Medtronic : Resolute (2010-2012) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - St Jude Medical : Optical coherence tomography (2010-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Medicines Company : Bivalirudine (2010-2012) <p>No additional information for the 2013 January - August period was submitted</p>
Ferreira J Rafael	<p>None</p> <p>Additional Information declared:</p>

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Ferreira J Rafael	17/06/2013 same relationships as 2012 i.e. no changes to declare.
Gersh Bernard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : DEFINE Study (2010-2011) - Boston Scientific : DSMB member (2010-2011-2012) - Cardiovascular Research Foundation : DSMB Member/Steering Committee (2012) - InspireMD : DSMB Member/Steering Committee (2012) - PPD Development, LP : DSMB Member/Steering Committee (2012) - Baxter Healthcare Corporation : DSMB Member/Steering Committee (2012) - St Jude Medical : DSMB Study "FAME II Trial" (2010-2011-2012) - GE Healthcare : General consulting (2010-2011) - Medispec Limited : Member of DSMB (2010-2011) - Orth-McNeil Janssen Scientific Affairs : Member of Executive Committee for ORBIT-AF Registry (2010-2011) - Amorcyte, Inc. : Member Scientific Advisory Board (2010) - Abbott Laboratories : Participate in the EXCEL Executive Operations Meeting (2010-2011) <p>Additional Information declared:</p> <p>15/05/2013 Same relationships as 2012, i.e. no changes to declare</p>

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Gersh Bernard	<p>21/05/2013 Data Safety Monitoring Board/Steering Committee for the following: PPD Development Cardiovascular Research Foundation InspireMD Boston Scientific Baxter Healthcare Corporation St. Jude Medical Merck</p> <p>30/07/2013 Data Safety Monitoring Board/Steering Committee for Medtronic needs to be added to the list above.</p> <p>30/07/2013 Data Safety Monitoring Board/Steering Committee for the following: PPD Development Cardiovascular Research Foundation InspireMD Boston Scientific Baxter Healthcare Corporation St. Jude Medical Merck Medtronic</p>
Gitt Anselm Kai	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulation Therapy (2010-2011-2012) - Eli Lilly : Anticoagulation Therapy (2010-2011-2012) - Bayer Healthcare : Anticoagulation Therapy (2010-2011) - Novo-Nordisk : Diabetes (2010-2011-2012) - Takeda Pharmaceuticals : Hypertension Therapy (2012) - Abbott : Interventional Cardiology (2010-2011-2012) - Astra Zeneca : Secondary Prevention (2010-2011-2012) - Novartis : Secondary Prevention (2010-2011-2012) - Sanofi Aventis : Secondary Prevention (2010-2011-2012) - Roche Pharma : Secondary Prevention (2010-2011-2012) - Bristol Myers Squibb : Secondary Prevention (2010-2011)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Gitt Anselm Kai	<ul style="list-style-type: none"> - Bristol Myers Squibb : Secondary Prevention (2012) - Merck Sharp & Dohme : Secondary Prevention (2010-2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Sanofi Aventis : Acute Coronary Syndromes (2010-2011-2012) - Merck Sharp & Dohme : Antiarrhythmic Therapy (2010-2011-2012) - Eli Lilly : Anticoagulation Therapy (2010-2011-2012) - Takeda Pharmaceuticals : Hypertension (2012) - Astra Zeneca : Secondary Prevention (2010-2011-2012) - Bristol Myers Squibb : Secondary Prevention (2010-2011-2012) - Merck Sharp & Dohme : Secondary Prevention (2010-2011-2012) - Servier : Stable Angina (2010-2011) <p>No additional information for the 2013 January - August period was submitted</p>
Hulot Jean-Sebastien	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anti-platelet (2010) - Medco Health Solutions : Anti-platelet agents (2010) - Biotronik : Pharmacogenetics (2010-2011) - Eli Lilly : speaker fees (2010) - Collectis : Stem cells (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biotronik : Anti-platelet (2011) - Biotronik : Anti-platelet (2010) - Medco Research Institute : Clopidogrel (2010) - Collectis : Stem Cells (2011-2012) <p>No additional information for the 2013 January - August period was submitted</p>
Marx Nikolaus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer AG : Anticoagulants (2012)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Marx Nikolaus	<ul style="list-style-type: none"> - Medtronic : CV devices (2010) - Sanofi Aventis-AVENTIS : CV, diabetes (2010) - Sanofi-Aventis : CV, Diabetes (2012) - Astra Zeneca : Diabetes (2010-2012) - Boehringer-Ingelheim : Diabetes (2010) - Novartis : Diabetes (2010-2012) - Sanofi Aventis : Diabetes (2010) - Lilly : Diabetes (2012) - Roche Pharma : Diabetes (2012) - Bristol Myers Squibb : Diabetes (2012) - Merck Sharp & Dohme : Diabetes (2010-2012) - Novo-Nordisk : Diabetes (2012) - Novo-Nordisk : diabetes (2010) - Boehringer-Ingelheim : Diabetes, CV (2012) - Boehringer-Ingelheim : Diabetes, CV (2010) - Pfizer : Lipids (2010) - Fournier Laboratories : Lipids (2012) - BMBF - German Ministry of Research and Education; DFG - German Research Foundation; IQWiG - Institute for Quality and Economic Viability in Health Service; DEGAM - German College of General Practitioners : Research (2010) - DFG - German Research Foundation : Research (2012) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2010) - Boehringer-Ingelheim : Diabetes (2010-2012) - Sanofi Aventis : Diabetes (2010) - Merck Sharp & Dohme : Diabetes (2010)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Marx Nikolaus	<ul style="list-style-type: none"> - Novo-Nordisk : diabetes (2010) - GlaxoSmithKline : diabetes; CV (2010) - Novartis : CV (2010) - BMBF - German Ministry of Research and Education; DFG - German Research Foundation; IQWiG - Institute for Quality and Economic Viability in Health Service; DEGAM - German College of General Practitioners : research (2010) - EASD : research (2010) E - Research funding (personal). <ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes (2012) - EASD : diabetes (2010-2012) - BMBF - German Ministry of Research and Education; DFG - German Research Foundation; IQWiG - Institute for Quality and Economic Viability in Health Service; DEGAM - German College of General Practitioners : research (2010) - BMBF - German Ministry of Research and Education; DFG - German Research Foundation : Research (2012) <p>Additional Information declared:</p> <p>23/05/2013 Same relationships as declared for 2013 on 27.02.2013 i. e. no changes to declare</p> <p>05/08/2013 In addition to declaration of May 23rd, 2013:</p> <p style="padding-left: 40px;">Financial Declaration - B: Payment to your Institution:</p> <p style="padding-left: 40px;">- Amgen GmbH</p>
Montalescot Gilles	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Cardiology (2012) - BMS : Cardiology (2012) - Boehringer-Ingelheim : Cardiology (2012) - Eli Lilly : Cardiology (2012) - Medtronic : Cardiology (2012) - Novartis : Cardiology (2012) - Biotronik : Cardiology (2012)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Montalescot Gilles	<ul style="list-style-type: none"> - Sanofi Aventis : Cardiology (2012) - Menarini : Cardiology (2012) - Roche Pharma : Cardiology (2012) - WebMD : Cardiology (2012) - TIMI group : Cardiology (2012) - Duke Institute : Cardiology (2012) - Europa : Cardiology (2012) - Lead-Up : Cardiology (2012) - Iroko Cardio : Cardiology (2012) - The Medicines Company : Cardiology (2012) - GSK : Cardiology (2012) - AstraZeneca : Cardiology (2012) - Springer : Cardiology (2012) - Wolters : Cardiology (2012) - Bayer : Interventional Cardiology (2011) - BMS : Interventional Cardiology (2011) - Boehringer-Ingelheim : Interventional Cardiology (2011) - Novartis : Interventional Cardiology (2011) - Portola Pharmaceuticals : Interventional Cardiology (2011) - WebMD : Interventional Cardiology (2011) - TIMI group : Interventional Cardiology (2011) - Duke Institute : Interventional Cardiology (2011) - Europa : Interventional Cardiology (2011) - Lead-Up : Interventional Cardiology (2011)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Montalescot Gilles	<ul style="list-style-type: none"> - Iroko Cardio : Interventional Cardiology (2011) - Atrium : Interventional Cardiology (2011) - MSD : Interventional Cardiology (2011) - GSK : Interventional Cardiology (2011) - Choice Pharma : Interventional Cardiology (2011) - CCS : Interventional Cardiology (2011) - CHUV : Interventional Cardiology (2011) - EuroRSCG : Interventional Cardiology (2011) - GLG : Interventional Cardiology (2011) - HUG : Interventional Cardiology (2011) - McKinsey : Interventional Cardiology (2011) - Navigant : Interventional Cardiology (2011) - Royal College Physicians : Interventional Cardiology (2011) - Springer : Interventional Cardiology (2011) - US Zurich : Interventional Cardiology (2011) - Wolters : Interventional Cardiology (2011) - BMS : Cardiology (2012) - Daiichi Sankyo : Cardiology (2012) - Eli Lilly : Cardiology (2012) - Medtronic : Cardiology (2012) - Pfizer : Cardiology (2012) - Biotronik : Cardiology (2012) - Sanofi Aventis : Cardiology (2012) - Menarini : Cardiology (2012)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Montalescot Gilles	<ul style="list-style-type: none"> - Roche Pharma : Cardiology (2012) - Abbott Vascular : Cardiology (2012) - Fédération Française de Cardiologie : Cardiology (2012) - Fondation de France : Cardiology (2012) - INSERM : Cardiology (2012) - Société Française de Cardiologie : Cardiology (2012) - The Medicines Company : Cardiology (2012) - AstraZeneca : Cardiology (2012) - Institut de France : Cardiology (2012) - Nanospheres : Cardiology (2012) - Stentys : Cardiology (2012) - Boston Scientific : Interventional Cardiology (2011) - Daiichi Sankyo : Interventional Cardiology (2011) - Medtronic : Interventional Cardiology (2011) - Pfizer : Interventional Cardiology (2011) - BRAHMS GmbH : Interventional Cardiology (2011) - Biotronik : Interventional Cardiology (2011) - Sanofi Aventis : Interventional Cardiology (2011) - Roche Pharma : Interventional Cardiology (2011) - Abbott Vascular : Interventional Cardiology (2011) - Cordis : Interventional Cardiology (2011) - Fédération Française de Cardiologie : Interventional Cardiology (2011) - Fondation de France : Interventional Cardiology (2011) - INSERM : Interventional Cardiology (2011)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Montalescot Gilles	<ul style="list-style-type: none"> - Société Française de Cardiologie : Interventional Cardiology (2011) - The Medicines Company : Interventional Cardiology (2011) - AstraZeneca : Interventional Cardiology (2011) - Asante : Interventional Cardiology (2011) - Eli-Lilly : Interventional Cardiology (2011) - Indegene : Interventional Cardiology (2011) - Institut de France : Interventional Cardiology (2011) - Nanospheres : Interventional Cardiology (2011) - Stentys : Interventional Cardiology (2011) - SGAM : Interventional Cardiology (2011) - Thrombosis Research Institute : Interventional Cardiology (2011) <p>Additional Information declared:</p> <p>31/07/2013 Pr Montalescot reports: research grants to the institution or consulting/lecture fees from Bayer, BMS, Boehringer Ingelheim, Duke Institute, Europa, GSK, Iroko, Lead-Up, Novartis, Springer, TIMI group, WebMD, Wolters, AstraZeneca, Biotronik, Eli Lilly, The Medicines Company, Medtronic, Menarini, Roche, Sanofi-Aventis, Pfizer, Accumetrics, Abbott Vascular, Daiichi-Sankyo, Fédération Française de Cardiologie, Fondation de France, INSERM, Institut de France, Nanospheres, Pfizer, Stentys, Société Française de Cardiologie.</p>
Opie Lionel Henry	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - NovoNordisk : Incretin therapy for diabetes (2011) - Servier : Supports University of Cape Town to provide part of salary of Director of the Institute I work in, Prof Karen Sliwa (2011) <p>Additional Information declared:</p> <p>08/03/2013 none new</p>

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Pfisterer Matthias	None No additional information for the 2013 January - August period was submitted
Prescott Eva	None Additional Information declared: 22/08/2013 No changes
Ruschitzka Frank	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biotronik : Devices (2010-2011-2012) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Drugs (2010-2011-2012) C - Receipt of royalties for intellectual property. - Cardioentis : Drugs (2010-2011-2012) D - Research funding (departmental or institutional). - Pfizer : Drugs (2010-2011-2012) No additional information for the 2013 January - August period was submitted
Sabate Tenas Manel	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : stent (2010) - Medtronic : stent (2010-2011-2012) - Abbott Vascular : Stent (2011-2012) - Cordis : stent (2010-2011)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Sabate Tenas Manel	<p>Additional Information declared:</p> <p>14/05/2013 Same relationships as 2012, i.e. no changes to declare.</p> <p>30/07/2013 Same relationships as 2012, i.e. no changes to declare</p>
Sechtem Udo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulation (2011-2012) - Novartis : Drugs (2011-2012) - Pfizer : Drugs (2011-2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Drugs (2011-2012) - Pfizer : Drugs (2012) - Johnson & Johnson : Stents (2011) <p>Additional Information declared:</p> <p>31/07/2013 No new information</p>
Senior Roxy	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bracco Pharmaceutical : Sonovue (2010-2011-2012) - Pfizer : Eplerenone (2011-2012) - Amgen : Epo protein (2011-2012) - Menarini : ranalozine (2012)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Senior Roxy	<p>D - Research funding (departmental or institutional). - TIMI group : None (2010-2011-2012)</p> <p>Additional Information declared:</p> <p>14/05/2013 There are no changes since my last declaration</p> <p>30/07/2013 Speaker fees received from Philips Healthcare,Eindhoven,Netherlands</p>
Taggart David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - VGS Pharma : external stent for vein grafts (2010) - Novadaq : intraoperative imaging (2010) - Abbott : speaking (2010-2011-2012) - Medtronic : speaking (2010) - Medtronic Foundation : speaking (2011-2012) - Cardiovascular Research Foundation : speaking (2011-2012) - Astra Zeneca : ticagrelor (2010) - Medtronic : stabilizer (2010) - Vascular Graft Solutions : pilot study (2011-2012) <p>No additional information for the 2013 January - August period was submitted</p>
Van der Wall Ernst	<p>None</p> <p>No additional information for the 2013 January - August period was submitted</p>
Vrints Christian Joseph Marie	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Abbott Vascular : nterventional cardiology (2011) - Medtronic : Pacing - interventional cardiology (2011)

Guidelines on Stable CAD 2013 (TF23) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Vrints Christian Joseph Marie	<ul style="list-style-type: none"> - Bayer : pharma (2010) D - Research funding (departmental or institutional). - Bracco Pharmaceutical : contrast dye (2012) - Abbott : interventional cardiology (2010) - Medtronic : Interventional cardiology devices (2012) - Medtronic : pacing (2010) <p>Additional Information declared:</p> <p>30/07/2013 same relationships as 2012 i.e. no changes to declare</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Aspirin, rivaroxaban (2011-2012) - Ferrer Internacional : Bivalirudin (2011) - Roche Pharma : Dalcetrapib (2011-2012) - Novartis : Heart Failure and elinogrel (2011-2012) - Daiichi Sankyo : Prasugrel (2011-2012) - Eli Lilly : Prasugrel (2011-2012) - Astra Zeneca : Ticagrelor (2011-2012) - Astra Zeneca : Ticagrelor (2012) <p>Additional Information declared:</p> <p>14/05/2013 No additional information to disclose in addition to my February 2013 disclosure</p>
Claeys Marc	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medicines Company : bivalirudine (2011-2012) - Eli Lilly : prasugrel, abciximab (2011-2012) - Abbott Vascular : stents- mitraclip (2011-2012) - Astra Zeneca : ticagrelor (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Medtronic : coronary stent and corevalve (2011-2012) <p>Additional Information declared:</p> <p>30/07/2013 'same relationships as 2012</p>

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Donner-Banzhoff Norbert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>E - Research funding (personal). - German Research Foundation : Health Services Research (public) (2011-2012) - German Ministry of Education and Research (BMBF) : Health Services Research (public) (2011-2012)</p> <p>Additional Information declared:</p> <p>13/05/2013 no changes from previous declarations</p>
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012) - Menarini : Trandolapril (2012)</p> <p>C - Receipt of royalties for intellectual property. - Astra-Zeneca : Ticagrelor (2012)</p> <p>Additional Information declared:</p> <p>13/05/2013 Only the product of Menarini should be Olmesartan.</p> <p>06/08/2013 No change</p>

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Frank Herbert	None No additional information for the 2013 January - August period was submitted
Funck-Brentano Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis CH : Adjudication Committee on an immunosuppressant (2011-2012) - Lundbeck : Cardiac safety of an antidepressant (2011-2012) - Shire HGT : Cardiac safety of an antidiarrheal drug (2012) - Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2011-2012) - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2011-2012) - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2011-2012) - MMV (CH) : Cardiac Safety of an antimalarial drug (2011) - Santhera (CH) : Cardiac Safety of an antimalarial drug (2011) - Sigma Tau : Cardiac Safety of an antimalarial drug (2011) - MMV (CH) : Cardiac Safety of two antimalarial drugs (2012) - Actelion : Consulting on the potential development of a calcium inhibitor (2012) - BMS : Discussion on an educational program for stroke prevention in AF (2012) - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety (2011) - CEPHALON : DSMB in an oncology phase IIb trial (2011-2012) - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel (2011) - Intracellular Therapies USA : Psychotropic drug development (2011) - Medco Health Solutions : co-investigator of a phase I study of an iv antiplatelet drug - payment to the hospital (2012) <p>Additional Information declared:</p> <p>26/05/2013 No new info since my DOI of 27/02/2013</p>

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Funck-Brentano Christian	30/07/2013 Personal consultant contract with MEDA France Scope : PK variability of Flecainide SR
Gaemperli Oliver	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet Agents, Speakers fees (2012) - Astra Zeneca : Antiplatelet therapy (2011) - Guerbet : Contrast agent for CT (2011) - General Electric : CT (2012) - Guerbet : Hybrid Imaging (2012) - Abbott Vascular : MitraClip (2011-2012) - GE Healthcare : Noninvasive Cardiac Imaging (SPECT, PET, CT) (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott Vascular : MitraClip (2012) - Abbott Vascular : MitraClip (2011) <p>Additional Information declared:</p> <p>13/05/2013 Adding to the 2012 DOI: Advisory board consultancy fee: Abbott Vascular</p> <p>30/07/2013 same relationships as 2013 and 2012</p>
Gonzalez Juanatey Jose Ramon	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Kowa : Speaker fee (2011-2012) - Boehringer-Ingelheim : Speaker fee, AB (2011-2012) - Servier : Speaker fee, AB (2011-2012) - Bayer Healthcare : Speaker fee, AB (2011-2012) - Roche Pharma : Speaker fee, AB (2011-2012)

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Gonzalez Juanatey Jose Ramon	<ul style="list-style-type: none"> - Esteve : Speaker fee, AB (2011-2012) - Almiral Spain : Speaker fee, AB (2011-2012) - Merck Sharp & Dohme : Speaker fee, AB (2011-2012) <p>No additional information for the 2013 January - August period was submitted</p>
Hamilos Michalis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Specifar Greece : Antiplatelet therapy (2012) - Terumo Inc : Interventional Cardiology (2011) - Abbott Vascular : Interventional Cardiology (2011) <p>Additional Information declared:</p> <p>06/08/2013 Minor speaking fees from Astra Zeneca (antiplatelet therapy) and Menarini (stable angina)</p>
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Boehringer-Ingelheim : Pradaxa (2012) - Bayer : Rivaroxiban (2012) - Astra Zeneca : Ticagrelor (2012) <p>Additional Information declared:</p> <p>14/05/2013 none</p> <p>30/07/2013 speakers honorarium GSK</p>

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Husted Steen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulant therapy (2011-2012) - Pfizer : Anticoagulant therapy (2011) - Bristol Myers Squibb : Anticoagulant therapy (2011-2012) - Astra Zeneca : Antiplatelet drugs (2011-2012) - Eli Lilly : Antiplatelet therapy (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulant therapy (2011-2012) - Pfizer : Anticoagulant therapy (2011) - Bristol Myers Squibb : Anticoagulant therapy (2011-2012) - Eli Lilly : Antiplatelet therapy (2011) <p>Additional Information declared:</p> <p>15/05/2013 Same relationships as in 2012, i.e. no new relationships to declare</p> <p>31/07/2013 No new information.</p>
James Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : coagulation inhibition (2012) - Merck Sharp & Dohme : coagulation inhibition (2011-2012) - Astra Zeneca : Platelet inhibition (2011) - Astra Zeneca : Platelet inhibition (2012) - Eli Lilly : platelet inhibition (2011-2012) - Medtronic : Stents and valves (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : platelet inhibition (2011-2012)

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
James Stefan	<ul style="list-style-type: none"> - Eli Lilly : platelet inhibition (2011-2012) - Medtronic : thrombus asp catheter (2011-2012) - Terumo Inc : thrombus asp catheter (2011-2012) - Vascular solutions : thrombus asp catheter (2011-2012) <p>No additional information for the 2013 January - August period was submitted</p>
Kervinen Kari	<p>None</p> <p>Additional Information declared:</p> <p>31/07/2013 No changes to declare.</p>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Lantheus Inc : Perfusion imaging tracer development (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Neurology (2011) - GE Healthcare : Neurology and molecular imaging (2011) - Servier : Vascular inflammation (2012) - Athera : vascular inflammation (2012) <p>No additional information for the 2013 January - August period was submitted</p>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet agents (2012) - Regado Biosciences : Antithrombotic agents (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antistaphylococcic vaccine (2012)

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Kolh Philippe H	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Cardiac valves (2012) - Medtronic : Cardiac valves (2012) - St Jude Medical : Cardiac valves (2012) - Boston Scientific : Coronary stents (2012) - Siemens Healthcare : Medical imaging (2012) - Johnson & Johnson : Thoracoscopic devices (2012) <p>Additional Information declared:</p> <p>15/05/2013 same relationships as 2012 i.e. no changes to declare</p>
Kristensen Steen Dalby	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : antitrombotics (2011) - Astra Zeneca : antitrombotics (2012) - Boehringer-Ingelheim : antitrombotics (2011-2012) - Eli Lilly : antitrombotics (2011-2012) - Pfizer : antitrombotics (2011-2012) - Bayer Healthcare : antitrombotics (2011-2012) - Medicines Company : antitrombotics (2011-2012) - Bristol Myers Squibb : antitrombotics (2011-2012) - Merck Sharp & Dohme : antitrombotics (2011) <p>Additional Information declared:</p>

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Kristensen Steen Dalby	14/05/2013 lecture fee Minarini 18/08/2013 Unchanged from 2012 with the change listed above.
Maggioni Aldo Pietro	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Aliskiren (2011-2012) - Oxford University : Anacetrapib (2012) - BMS : Apixaban (2011) - Actelion : Bosentan (2011-2012) - Amgen : Derbapoinetin (2011-2012) - Oxford University : Exanatide (2011-2012) - Servier : Ivabradine (2011-2012) - Novartis : LCZ 696 (2012) - Bayer : Rivaroxiban (2012) - Cardioentis : Ularitide (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - GlaxoSmithKline : Acute coronary syndromes (2011-2012) - Oxford University : Anacetrapib (2012) - Boehringer-Ingelheim : Atrial fibrillation (2011) - Sanofi Aventis : Diabetes (2011) - Bayer : Rivaroxaban (2012) - NIH : Stable coronary disease (2012) <p>Additional Information declared:</p> 14/05/2013 same relationships as 2012 i.e. no changes to declare

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Maggioni Aldo Pietro	<p>02/08/2013 ADD in the section Financial Declaration A - Direct Personal payment:</p> <p>Company: Bayer Product or Therapeutic Area: BAY 94-8862</p> <p>Company: Abbott Vascular Product or Therapeutic Area: Mitraclip</p> <p>DELETE in the section Financial Declaration D - Research Funding (departmental or institutional) the following Company: GlaxoSmithKline Product or Therapeutic Area: Acute Coronary Syndromes</p>
Pries Axel Radlach	<p>None No additional information for the 2013 January - August period was submitted</p>
Romeo Francesco	<p>None No additional information for the 2013 January - August period was submitted</p>
Ryden Lars	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Cardiology; Course organisation, lecture (2011-2012) - Sanofi Aventis : Diabetes and cardiovascular disease. Advisor boards, lecture fees (2011) - BMS : Diabetes and cardiovascular disease. Advisory committee fee (2011-2012) - Astra Zeneca : Diabetes and cardiovascular disease; Advisory Board and occasional lecture fees (2011-2012) - Roche Pharma : Diabetes and cardiovascular disease; Consultant, lecture fees (2011-2012) - Bayer : Diabetes and cardiovascular disease; Lecture fees (2012) - Bayer : Diabetes and cardiovascular disease; Lecture fees (2011) - Amgen : Member DSMB (2011)

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
<p>Ryden Lars</p>	<p>D - Research funding (departmental or institutional). - Roche Pharma : Diabetes and cardiovascular disease (2012) - Astra Zeneca : Cardiology (2011) - Roche Pharma : Cardiology (2011)</p> <p>Additional Information declared:</p> <p>13/05/2013 I have become honorary member of the Moldavian and the Romanian Societies of Cardiology in April 2013. 13/05/2013 Besides the new honorary memberships no further changes, 31/07/2013 Nothing new -my declaration is still valid July 31 2013.</p>
<p>Simoons Maarten L</p>	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : anticoagulant (2011) - Boehringer-Ingelheim : Dabigatran (2012) - Sanofi Aventis : new lipid lowering drug, under investigation (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
<p>Steg Philippe Gabriel</p>	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : antianginal agents (2011-2012) - Bayer : anticoagulants (2011-2012) - Astellas : Anticoagulants (2011) - Astra Zeneca : antiplatelet agents (2011-2012) - Daiichi Sankyo : antiplatelet agents (2011-2012) - Boehringer-Ingelheim : antithrombotics (2011-2012) - Sanofi Aventis : antithrombotics (2011-2012) - GlaxoSmithKline : antithrombotics (2011-2012) - Medicines Company : antithrombotics (2011-2012)</p>

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Steg Philippe Gabriel	<ul style="list-style-type: none"> - Bristol Myers Squibb : antithrombotics (2011-2012) - Lilly : antithrombotics and lipid lowering drugs (2011-2012) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Contrast agents (2011-2012) - Vivus : Drugs for obesity (2011-2012) - Amarin : Lipid compounds (2011-2012) - Medtronic : stents (2011-2012) - Aterovax : Biomarkers (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Sanofi Aventis : Clinical trial on lipids (2011-2012) - Servier : Registry on coronary artery disease (2011-2012) <p>No additional information for the 2013 January - August period was submitted</p>
Timmis Adam D	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Servier : Angina (2012) - Elsevier : Cardiology literature (ECG poster) (2011) <p>Additional Information declared:</p> <p>13/05/2013 Advisory Board - Servier (may 2013)</p> <p>05/08/2013 Same relationships as previously declared</p>
Valgimigli Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medicines Company : bivalirudin (2011) - Terumo Inc : Interventional cardiology (2011-2012) - Abbott Laboratories : ngal (2011)

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Valgimigli Marco	<ul style="list-style-type: none"> - Accumetrics : Platlet Function Assay (2011-2012) - Roche Pharma : PPAR alpha/gamma (2011) - Medtronic : stent (2011-2012) - Abbott Laboratories : stent (2012) - Abbott Vascular : stent (2011-2012) - Cordis : stent (2011-2012) - CID : stent (2011-2012) - Astra Zeneca : ticagrelor (2011-2012) - Chiesi Pharma : tirofiban (2011-2012) - Iroko Cardio : Tirofiban (2011-2012) - Abbott Laboratories : ngal (2011) <p>Additional Information declared:</p> <p>27/05/2013 No changes to declare.</p>
Wijns William	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : device (2012) - Boston Scientific : device (2012) - Edwards Lifesciences : device (2012) - Medtronic : device (2012) - St Jude Medical : device (2012)

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Wijns William	<ul style="list-style-type: none"> - Biotronik : device (2012) - Terumo Inc : device (2012) - Abbott Vascular : device (2012) - Cordis : device (2012) - Orbus Nech : device (2012) - MICELL : device (2012) - Vessix : device (2012) - Tryton : device (2012) - GlaxoSmithKline : drug (2012) - Astra Zeneca : pharma (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Cardio3 Biosciences : cell therapy (2012) - Boston Scientific : device (2012) - Medtronic : device (2012) - St Jude Medical : device (2012) - Biotronik : device (2012) - Abbott Laboratories : device (2012) - MICELL : device (2012) - Therabel : drug (2012) <p>No additional information for the 2013 January - August period was submitted</p>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet drug (2012) - Eli Lilly : Antiplatelet drug (2012) - Abbott : Stent (2012) - Biosensors : Stent (2012)

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Boston Scientific : Stent (2012) - Medtronic : Stent (2012) - Biotronik : Stent (2012) - Cordis : Stent (2012) - Edwards Lifesciences : TAVI (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : OCT (2012) - Abbott : Stent (2012) - Biosensors : Stent (2012) - Medtronic : Stent (2012) - Biotronik : Stent (2012) - Cordis : Stent (2012) <p>Additional Information declared:</p> <p>31/07/2013 same declaration as before and no changes</p>
Yildirim Aylin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Merck Sharp & Dohme : investigator in a multicenter study (Improve it) (2012) <p>Additional Information declared:</p> <p>30/07/2013 No change since my last annual declaration.</p>

Guidelines on Stable CAD 2013 (TF23) - Document Reviewers

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Vascular : Help in Design Echocardiographic protocol (2012) - Merck Sharp & Dohme : Lecture (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - FP7 EU research program : CV Imaging (2012)</p> <p>C - Receipt of royalties for intellectual property. - Springer : ESC Textbook of CV Imaging (2012)</p> <p>Additional Information declared:</p> <p>13/05/2013 Same</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Siemens Healthcare : CT (2012) - Servier : Imaging (2012) - Guerbet : Imaging (2012) <p>Additional Information declared:</p> <p>14/05/2013 Same relationships as last year, nothing new to declare.</p> <p>31/07/2013 NO new information</p>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2012) - Edwards Lifesciences : transcatheter valve implantation (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2012) - Edwards Lifesciences : transcatheter valve implantation (2012) <p>Additional Information declared:</p> <p>13/05/2013 no changes compared to 2012</p>
Bax Jeroen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Farma (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Bax Jeroen	<ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valves (2012) - GE Healthcare : Imaging (2012) - Lantheus Inc : Imaging (2012) - Boston Scientific : Pacing (2012) - Medtronic : Pacing (2012) - St Jude Medical : Pacing (2012) - Biotronik : Pacing (2012) <p>Additional Information declared:</p> <p>23/06/2013 Nothing has changed</p>
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Aspirin, rivaroxaban (2012) - Roche Pharma : Dalcetrapib (2012) - Novartis : Heart Failure and elinogrel (2012) - Daiichi Sankyo : Prasugrel (2012) - Eli Lilly : Prasugrel (2012) - Astra Zeneca : Ticagrelor (2012) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2012) <p>Additional Information declared:</p> <p>14/05/2013 No additional information to disclose in addition to my February 2013 disclosure</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Deaton M Christi	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012)</p> <p>Additional Information declared:</p> <p>13/05/2013 Funding from Novo Nordisk has ended, no other changes to report</p> <p>13/05/2013 no other new information</p>
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012) - Menarini : Trandolapril (2012)</p> <p>C - Receipt of royalties for intellectual property. - Astra-Zeneca : Ticagrelor (2012)</p> <p>Additional Information declared:</p> <p>13/05/2013 Only the product of Menarini should be Olmesartan. That is all I can change</p> <p>06/08/2013 No change</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Fagard Robert	<p>None</p> <p>Additional Information declared:</p> <p>03/06/2013 No changes to declare</p> <p>07/08/2013 No changes to declare</p>
Ferrari Roberto	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulant and diabetes. Dagabitran (2012) - Medical Trials Analysis : Consultant in Clinical Trials (2012) - Servier : Myocardial ischemia and heart failure. Perindopril, ivabradine, amlodipine, trimetazidine (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Schering-Plough : Anti-platelet agent TRACER (2012) - Fondazione Salvatore Maugeri : General (2012) - Servier : Perindopril, ivabradine, amlodipine CLARifY and SIGNifY (2012) <p>Additional Information declared:</p> <p>14/05/2013 No new information</p>
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Boehringer-Ingelheim : Pradaxa (2012) - Bayer : Rivaroxiban (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
<p>Hasdai David</p>	<p>- Astra Zeneca : Ticagrelor (2012)</p> <p>Additional Information declared:</p> <p>14/05/2013 none</p> <p>30/07/2013 speakers honorarium GSK</p>
<p>Hoes Arno</p>	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012)</p> <p>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)</p> <p>D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p>Additional Information declared:</p> <p>03/06/2013 no changes to declare</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - BMS : cardiovascular (2012) - Boehringer-Ingelheim : cardiovascular (2012) - Daiichi Sankyo : cardiovascular (2012) - Medtronic : cardiovascular (2012) - Pfizer : cardiovascular (2012) - St Jude Medical : cardiovascular (2012) - Sanofi Aventis : cardiovascular (2012) - Meda pharma : cardiovascular (2012) - Merck Sharp & Dohme : cardiovascular (2012) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : cardiovascular (2012) - Bayer Healthcare : cardiovascular (2012) - Portola Pharmaceuticals : cardiovascular (2012) - BMS / Pfizer alliance : cardiovascular (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : cardiovascular (2012) - Sanofi Aventis : cardiovascular (2012) - Meda pharma : cardiovascular (2012) <p>Additional Information declared:</p> <p>14/05/2013 Consulting fees and honoraria 3M Medica</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p>MEDA Pharma AstraZeneca Bayer Healthcare Biosense Webster Boehringer Ingelheim Daiichi-Sankyo German Cardiac Society MEDA Pharma Medtronic Merck MSD Otsuka Pharma Pfizer / BMS sanofi Servier Siemens TAKEDA</p> <p>In addition, I have received travel support for meetings from the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), a registered branch of ESC, and from the German Atrial Fibrillation Competence NETwork (AFNET)</p> <p>Research Grants 3M Medica / MEDA Pharma Cardiovascular Therapeutics Medtronic OMRON SANOFI St. Jude Medical German Federal Ministry for Education and Research (BMBF) Fondation Leducq</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p>German Research Foundation (DFG) European Union (EU)</p>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Perfusion imaging tracer development (2012)</p> <p>D - Research funding (departmental or institutional). - Servier : Vascular inflammation (2012) - Athera : vascular inflammation (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet agents (2012) - Regado Biosciences : Antithrombotic agents (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme : Antistaphylococcic vaccine (2012)</p> <p>D - Research funding (departmental or institutional). - Edwards Lifesciences : Cardiac valves (2012) - Medtronic : Cardiac valves (2012) - St Jude Medical : Cardiac valves (2012) - Boston Scientific : Coronary stents (2012) - Siemens Healthcare : Medical imaging (2012) - Johnson & Johnson : Thoracoscopic devices (2012)</p> <p>Additional Information declared:</p> <p>15/05/2013 same relationships as 2012 i.e. no changes to declare</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Heart Failure (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Brilique (2012) - Servier : Coversyl (2012) - Abbott Vascular : MitraClip (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Linhart Ales	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Arterial hypertension (2012) - Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012) - GlaxoSmithKline : Atherosclerosis (2012) - Merck Sharp & Dohme : Dyslipidemia (2012) - Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012) - Shire HGT : Fabry disease (2012) - Genzyme : Fabry disease (2012) - Actelion : Pulmonary hypertension (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Shire HGT : Fabry disease (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Nihoyannopoulos Petros	<p>None</p> <p>No additional information for the 2013 January - August period was submitted</p>
Piepoli Massimo Francesco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Anti-dyslipidemic therapy (2012)</p> <p>Additional Information declared:</p> <p>13/05/2013 'same relationships as 2012 i.e. no changes to declare': 30/07/2013 'same relationships as 2012 i.e. no changes to declare':</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - BMS : anticoagulant (2012) - Boehringer-Ingelheim : anticoagulant (2012) - Respicardia : anticoagulant (2012) - Abbott Vascular : devices (2012) - Amgen : heart failure (2012) - Novartis : heart failure (2012) - Johnson & Johnson : heart failure (2012) - Bayer Healthcare : heart failure (2012) - Vifor Pharma ltd : heart failure (2012) - Corthera : heart failure (2012) - Coridea : heart failure (2012) - Pfizer : heart failure, anticoagulant (2012) - Servier : heart failure, coronary artery disease (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Vifor Pharma ltd : heart failure (2012) <p>Additional Information declared:</p> <p>14/05/2013 update to DOI 2012: - Abbott Vascular</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Sirnes Per Anton	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NORMA on behalf of Janssen Cilar : Invest fee CANVAS study (2012) - Quintiles on behalf of Novartis : Investig fee CANTOS study (2012) - GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012) - SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012) - Merck Sharp & Dohme : Investigator fee HPS2-THRIVE STUDY (2012) - Boehringer Ingelheim : Investigator Fee Relyable study (2012) - Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)</p> <p>Additional Information declared: No additional information for the 2013 January - August period was submitted</p>
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - sanodi-aventis : Dronedarone-antiarrhythmic agent (2012)</p> <p>E - Research funding (personal). - Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Aspirin, Rivaroxaban (2012) - Amgen : Darbopoietin (2012) - Servier : Ivabradine, Phase II investigational products (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, Phase II investigational products (2012)</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
	<p>Additional Information declared:</p> <p>13/05/2013 No new info.</p>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Cardiomems : implanted pulmonary artery pressure sensor (2012) - United Therapeutics : Pulmonary arterial hypertension (2012) - GSK : pulmonary arterial hypertension - ambrisentan (2012) - Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012) - Lilly : pulmonary arterial hypertension - tadalafil (2012) - AOP : Pulmonary arterial hypertension - treprostinil (2012) - Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2012) - Bristol Myers Squibb : thromboembolic disease - Apixaban (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Pulmonary hypertension (2012) - Sanofi Aventis : Thromboembolic disease (2012) <p>No additional information for the 2013 January - August period was submitted</p>
Wijns William	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : device (2012) - Boston Scientific : device (2012) - Edwards Lifesciences : device (2012) - Medtronic : device (2012) - St Jude Medical : device (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Wijns William	<ul style="list-style-type: none"> - Biotronik : device (2012) - Terumo Inc : device (2012) - Abbott Vascular : device (2012) - Cordis : device (2012) - Orbus Nech : device (2012) - MICELL : device (2012) - Vessix : device (2012) - Tryton : device (2012) - GlaxoSmithKline : drug (2012) - Astra Zeneca : pharma (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Cardio3 Biosciences : cell therapy (2012) - Boston Scientific : device (2012) - Medtronic : device (2012) - St Jude Medical : device (2012) - Biotronik : device (2012) - Abbott Laboratories : device (2012) - MICELL : device (2012) - Therabel : drug (2012) <p>No additional information for the 2013 January - August period was submitted</p>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet drug (2012) - Eli Lilly : Antiplatelet drug (2012) - Abbott : Stent (2012) - Biosensors : Stent (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Boston Scientific : Stent (2012) - Medtronic : Stent (2012) - Biotronik : Stent (2012) - Cordis : Stent (2012) - Edwards Lifesciences : TAVI (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : OCT (2012) - Abbott : Stent (2012) - Biosensors : Stent (2012) - Medtronic : Stent (2012) - Biotronik : Stent (2012) - Cordis : Stent (2012) <p>Additional Information declared:</p> <p>31/07/2013 same declaration as before and no changes</p>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott Vascular : Help in Design Echocardiographic protocol (2012) - Merck Sharp & Dohme : Lecture (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - FP7 EU research program : CV Imaging (2012) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer : ESC Textbook of CV Imaging (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	Additional Information declared: 13/05/2013 Same

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.